Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Fingolimod-A sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes.
Fingolimod modulates microglial activation to augment markers of remyelination.
Disease-modifying treatments for progressive multiple sclerosis.
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Stress and the risk of multiple sclerosis.
Multiple sclerosis.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Amyloid precursor protein at node of Ranvier modulates nodal formation.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.

Pages